Generic Name and Formulations:
Fluorouracil 0.5% (0.35% in microspheres); crm.
Bausch Health Companies Inc.
Indications for CARAC:
Multiple actinic or solar keratoses of the face and anterior scalp.
≥18yrs: Wash and dry area. Wait 10 minutes. Apply thin film to skin where lesions appear once daily for up to 4 weeks. Do not occlude. May apply sunscreen/ moisturizer 2 hours later. Wash hands after use.
<18yrs: not recommended.
Dihydropyrimidine dehydrogenase (DPD) deficiency. Women of childbearing potential. Pregnancy (Cat.X).
Discontinue if symptoms of DPD deficiency develop (e.g., abdominal pain, bloody diarrhea, vomiting, fever, chills). Ulcerated or inflamed skin. Avoid eyes, mucous membranes, exposure to sun or UV light. Nursing mothers: not recommended.
Application site reaction (may persist 2 weeks after drug is stopped), eye irritation.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- Brentuximab Vedotin Combo Active in Older Patients With Hodgkin Lymphoma
- Prostate Cancer Drug Resistance Mediated by Epigenetic Changes
- Nilotinib and Dasatinib Confer Similar Outcomes for Chronic-Phase CML
- Later-Line Treatments for Metastatic Urothelial Carcinoma of the Bladder
- Higher Doses of Image-Guided Neoadjuvant Radiation Therapy Found to Be Safe in Locally Advanced NSCLC: Study